Table 1.

Example of drugs used in regional studies

Drug	Drug Class	Ref. No.
Acetylcholine	Vasodilator: cholinergic	64
Adenosine	Vasodilator: adenosine	165
Aminophylline	Adenosine antagonist	165
Angiotensin II*	Angiotensin II	16
Ascorbic acid	Vitamin C	275
Atropine	Cholinergic antagonist	20
Barium chloride (BaCl2)*	KIR channels	45
BHT-933*	α2-Adrenergic agonist	128
BQ123*	ETA receptor antagonist	13
BQ788*	ETB receptor antagonist	55
Celecoxib†	Cyclooxygenase-2 inhibitor	64
Clonidine	α2-Adrenergic agonist	167
Dexmedetomidine	α2-Adrenergic agonist	168
Dipyridamole	Adenosine transporter antagonist	164
Endothelin-1*	Vasoconstrictor: endothelin-1	188
Glibencamide*	ATP-sensitive potassium (KATP) channel antagonist	238
Ibuprofen†	Cyclooxygenase inhibitor	11
Indomethacin†	Cyclooxygenase inhibitor	259
Isoproterenol	β1- and β2-Adrenergic agonist	104
Ketorolac	Cyclooxygenase inhibitor	30
Milrinone	Phosphodiesterase III inhibitor	65
NG-monomethyl-l-arginine acetate*	Nitric oxide synthase inhibitor	186
Nitroglycerin	Vasodilator: nitric oxide	218
Norepinephrine	α- and β1-Adrenergic agonist	36
Ouabain octahydrate*	Na+/K+-ATPase	45
Phentolamine	α1- and α2-Adrenergic antagonist	297
Phenylephrine	α1-Adrenergic agonist	168
Prazosin*	α1-Adrenergic antagonist	167
Propranolol	β1- and β2-Adrenergic antagonist	297
Prostacyclin	Vasodilator: prostacyclin	186
Sildenafil†	Phosphodiesterase V inhibitor	137
Sodium Nitroprusside	Vasodilator: nitric oxide	218
Tyramine*	Vasoconstrictor: endogenous norepinephrine	31
Yohimbine*	α1-Adrenergic antagonist	56

^*Historical (not Food and Drug Administration approved, limited availability, or no longer manufactured) or

^†orally administered and vascular study was preformed regionally.